SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Longtime Biogen Exec Jumps Ship to Become COO of Scangos' Bay Area Startup
Business
Longtime Biogen Exec Jumps Ship to Become COO of Scangos’ Bay Area Startup
August 29, 2017
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Biogen Shows Off More Positive Alzheimer’s Trial Data
August 28, 2017
 · 
3 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
Biogen Gained $1 Billion Overnight After Becoming Goldman Sachs’ Favorite Biotech
August 17, 2017
 · 
3 min read
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Business
Vicarius Pharma Launches With $21.8 Million and Will be Helmed by Former Biogen-Elan Exec
August 14, 2017
 · 
2 min read
Deals
Biogen Is Hunting For Neuroscience Deals Of All Sizes
July 26, 2017
 · 
1 min read
Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Job Trends
Biogen May Cut Jobs, Shutter Facilities to Streamline Ops and Free Up $400 Million for R&D
July 25, 2017
 · 
3 min read
How Biogen Makes Most of Its Cash
Genetown
How Biogen Makes Most of Its Cash
July 14, 2017
 · 
3 min read
Business
Big Expectations For Biogen’s New VP Of Governmental Affairs
July 12, 2017
 · 
1 min read
Drug Development
Why Biogen Spinoff Bioverativ’s Anemia Drug Could Be A Blockbuster
July 11, 2017
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 23, 2025
 · 
13 min read
Press Releases
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS
December 11, 2025
 · 
6 min read
Press Releases
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
December 10, 2025
 · 
8 min read
Press Releases
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
December 9, 2025
 · 
11 min read
Press Releases
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
 · 
19 min read
Press Releases
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025
December 4, 2025
 · 
24 min read
Press Releases
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 3, 2025
 · 
21 min read
Press Releases
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Press Releases
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
December 2, 2025
 · 
16 min read
Load More